Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPAGT1 | Q9H3H5 | 5/20 | 0.61 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.32 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.32 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13618306 | 0.89 | DPAGT1 (0.76) | DPAGT1P2RY6P2RY2P2RY4 | |
| SCHEMBL13625829 | 0.86 | DPAGT1 (0.62) | DPAGT1P2RY6P2RY2P2RY4 | |
| SCHEMBL14598954 | 0.86 | DPAGT1 (0.52) | DPAGT1 | |
| SCHEMBL14598941 | 0.86 | DPAGT1 (0.52) | DPAGT1 | |
| SCHEMBL14583636 | 0.85 | DPAGT1 (0.49) | DPAGT1 | |
| SCHEMBL14598940 | 0.85 | DPAGT1 (0.51) | DPAGT1 | |
| SCHEMBL14598955 | 0.85 | DPAGT1 (0.51) | DPAGT1 | |
| SCHEMBL14599066 | 0.84 | DPAGT1 (0.52) | DPAGT1 | |
| SCHEMBL14599055 | 0.82 | DPAGT1 (0.49) | DPAGT1 | |
| SCHEMBL14599072 | 0.81 | DPAGT1 (0.49) | DPAGT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281054-A1 | COMPOSITIONS AND METHODS COMPRISING CAPURAMYCIN ANALOGUES | SEQUELLA, INC. | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281054-A1 | COMPOSITIONS AND METHODS COMPRISING CAPURAMYCIN ANALOGUES | TTPA, PHOSPHO1, CAPG | DPAGT1 309/4885P2RY6 3295/4885P2RY2 4464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.